Discontinue use upon appearance of rash or other possible allergic phenomena for which an alternative etiology cannot be identified. Patients w/ a history of allergic reactions. Long elimination t
½. Anxiety & insomnia. Significant wt loss especially in underwt depressed patients. Possible hypomania or mania primarily in unipolar depressives. Patients w/ a history of convulsive disorders. Avoid concurrent administration w/ electroshock therapy. Sexual dysfunction symptoms. Assess electrolyte levels of bulimic patients prior to initiation of treatment. Possibility of suicide attempt is inherent in depression & may persist until significant remission occurs; closely supervise high-risk patients throughout therapy & consider the possible need for hospitalization. Patients w/ concomitant systemic illness especially diseases/conditions affecting metabolism or hemodynamic responses; recent history of MI or unstable heart disease. Patients suffering from anorexia. May alter glycemic control in patients w/ diabetes. Hyponatremia. Altered platelet function. Carefully evaluate patients for history of drug abuse; closely observe for signs of fluoxetine misuse or abuse. May impair cognitive & motor performance; driving an automobile or performing hazardous tasks. Severe renal impairment. Impaired liver function including cirrhosis. Women of childbearing potential. Pregnancy & lactation. Childn <18 yr. Elderly >60 yr.
Sign Out
